methyl 1-(p-aminophenyl)cyclopentanecarboxylate | 135569-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 1-(p-aminophenyl)cyclopentanecarboxylate
• 英文别名: methyl 1-(4-aminophenyl)cyclopentanecarboxylate；1-(4-amino-phenyl)cyclopentanecarboxylic acid methyl ester；Methyl 1-(4-aminophenyl)cyclopentane-1-carboxylate
• CAS: 135569-20-9
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: YRAFDBGZZIBBLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-(p-aminophenyl)cyclopentanecarboxylate 在 盐酸 、 氯化亚砜 、 sodium azide 作用下， 以 苯 为溶剂， 反应 40.0h， 生成 2-(diethylamino)ethyl 1-(p-1-tetrazolylphenyl)cyclopentanecarboxylate
  参考文献：
  名称：

  Muscarinic receptor binding profile of para-substituted caramiphen analogs

  摘要：

  Para-substituted analogues of the antimuscarinic agent caramiphen were synthesized and evaluated for their ability to bind to the M1 and M2 subtypes of the muscarinic receptor. The purpose of the set was to look for a possible relationship in binding affinity or receptor subtype selectivity with aromatic substituent parameters such as Hammett's-sigma or Hansch's pi-values. It is felt this could be determined initially with only four properly chosen substituents. In this approach, substituents were chosen which have an extreme value for sigma and for pi, in a positive and negative direction, in all combinations. The substituents chosen for examination were amino (-sigma, -pi); 1-pyrrolidinyl (-sigma, +pi); 1-tetrazolyl (+sigma, -pi), and iodo (+sigma, +pi). It was determined in this research that caramiphen binds with high affinity (K(i) = 1.2 nM) and is selective for the M1 over M2 muscarinic receptor subtype (26-fold). An examination of para-substitution reveals that compounds with electron-withdrawing (+sigma) substituents showed M1 selectivity, while the derivatives with electron-donating groups (-sigma) were nonselective in the binding assays. On the basis of this finding, the nitro and cyano derivatives were prepared and found to be M1 selective. The +sigma derivatives showed a decrease in M2 affinity while the p-nitro and p-iodo derivatives retained approximately equal affinity as caramiphen for the M1 site. The nitro- and iodocaramiphen derivatives were as potent (M1, K(i) = 5.52 and 2.11 nM, respectively) and showed a greater selectivity of M1 over M2 binding than the M1 prototypical agent pirenzepine (M1, K(i) = 5.21 nM).

  DOI：

  10.1021/jm00114a005
• 作为产物：
  描述：

  1-(4-nitro-phenyl)-cyclopentanecarbonyl chloride 在 platinum on activated charcoal 氢气 作用下， 以 甲醇 、 苯 为溶剂， 反应 4.0h， 生成 methyl 1-(p-aminophenyl)cyclopentanecarboxylate
  参考文献：
  名称：

  Muscarinic receptor binding profile of para-substituted caramiphen analogs

  摘要：

  Para-substituted analogues of the antimuscarinic agent caramiphen were synthesized and evaluated for their ability to bind to the M1 and M2 subtypes of the muscarinic receptor. The purpose of the set was to look for a possible relationship in binding affinity or receptor subtype selectivity with aromatic substituent parameters such as Hammett's-sigma or Hansch's pi-values. It is felt this could be determined initially with only four properly chosen substituents. In this approach, substituents were chosen which have an extreme value for sigma and for pi, in a positive and negative direction, in all combinations. The substituents chosen for examination were amino (-sigma, -pi); 1-pyrrolidinyl (-sigma, +pi); 1-tetrazolyl (+sigma, -pi), and iodo (+sigma, +pi). It was determined in this research that caramiphen binds with high affinity (K(i) = 1.2 nM) and is selective for the M1 over M2 muscarinic receptor subtype (26-fold). An examination of para-substitution reveals that compounds with electron-withdrawing (+sigma) substituents showed M1 selectivity, while the derivatives with electron-donating groups (-sigma) were nonselective in the binding assays. On the basis of this finding, the nitro and cyano derivatives were prepared and found to be M1 selective. The +sigma derivatives showed a decrease in M2 affinity while the p-nitro and p-iodo derivatives retained approximately equal affinity as caramiphen for the M1 site. The nitro- and iodocaramiphen derivatives were as potent (M1, K(i) = 5.52 and 2.11 nM, respectively) and showed a greater selectivity of M1 over M2 binding than the M1 prototypical agent pirenzepine (M1, K(i) = 5.21 nM).

  DOI：

  10.1021/jm00114a005

文献信息

• Novel propanamides as fatty acid amide hydrolase inhibitors
  作者：Alessandro Deplano、Carmine Marco Morgillo、Monica Demurtas、Emmelie Björklund、Mariateresa Cipriano、Mona Svensson、Sanaz Hashemian、Giovanni Smaldone、Emilia Pedone、F. Javier Luque、Maria G. Cabiddu、Ettore Novellino、Christopher J. Fowler、Bruno Catalanotti、Valentina Onnis

  DOI：10.1016/j.ejmech.2017.05.033

  日期：2017.8

  Fatty acid amide hydrolase (FAAH) has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol. FAAH inhibition represents a promising strategy to activate the cannabinoid system, since it does not result in the psychotropic and peripheral side effects characterizing the agonists of the cannabinoid receptors

  脂肪酸酰胺水解酶（FAAH）在控制大麻素信号传导中起着关键作用，通过内源性大麻素anandamide的水解以及某些组织中的2-花生四烯酸甘油酯来进行。FAAH抑制代表了激活大麻素系统的一种有前途的策略，因为它不会导致表征大麻素受体激动剂的精神和外围副作用。在这里，我们介绍一种新型的profen衍生物N的发现。-（杂芳基）-2-（4-（（2-（三氟甲基）吡啶-4-基）氨基）苯基）丙酰胺，作为FAAH抑制剂。酶法测定显示对FAAH的效力范围从纳摩尔到微摩尔，并且大多数化合物对环加氧酶的两种同工型均缺乏活性。还介绍了广泛的结构活性研究和该系列先导化合物的结合方式的定义。在大鼠和小鼠FAAH上对该系列所选化合物进行的动力学分析表明，化学结构的轻微修饰可能会影响结合模式，并导致竞争性（TPA1）或非竞争性（TPA14）抑制模式。
• NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS
  申请人：Alexander Christopher W.

  公开号：US20100144722A1

  公开（公告）日：2010-06-10

  Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.

  提供了式(I)及其立体异构体和/或药学上可接受的盐的新型杂环化合物。此外，还提供了形成新型杂环化合物、其立体异构体和/或药学上可接受的盐的方法。
• 阿帕替尼的制备方法
  申请人：苏州富士莱医药股份有限公司

  公开号：CN109879805B

  公开（公告）日：2020-08-07

  一种阿帕替尼的制备方法，将4‑(叔丁氧羰基氨基)苯乙酸烷基酯与1,4‑二卤丁烷进行缩合反应，得到1‑[4‑(叔丁氧羰基氨基)苯基]环戊烷甲酸烷基酯；将所得物进行脱保护反应，得到1‑(4‑氨基苯基)环戊烷甲酸烷基酯；将所得物与2‑氯烟酰氯进行酰胺化反应，得到1‑4‑[(2‑氯吡啶‑3‑基)羰基氨基]苯基}环戊烷甲酸烷基酯；将所得物与4‑氨甲基吡啶进行取代反应，得到1‑4‑[(2‑((4‑吡啶基甲基)氨基)吡啶‑3‑基)羰基氨基]苯基}环戊烷甲酸烷基酯；将所得物进行酰胺化反应，得到1‑4‑[(2‑((4‑吡啶基甲基)氨基)吡啶‑3‑基)羰基氨基]苯基}环戊烷甲酰胺；最后进行脱水，得到成品。
• Novel Biccyclic Compounds As GATA Modulators
  申请人：De Dibyendu

  公开号：US20100144731A1

  公开（公告）日：2010-06-10

  Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.

  提供了新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐。此外，还提供了形成新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐的方法。
• Biccyclic compounds as GATA modulators
  申请人：Dr. Reddy's Laboratories Limited

  公开号：US07989463B2

  公开（公告）日：2011-08-02

  Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided: wherein R1, R2, m, and n are defined herein.

  本发明提供了式(I)的新型双环化合物、立体异构体和/或其药学上可接受的盐，以及新型双环化合物立体异构体和/或其药学上可接受的盐的药学上可接受的盐。此外，本发明还提供了制备新型双环化合物、立体异构体和/或其药学上可接受的盐，以及新型双环化合物立体异构体和/或其药学上可接受的盐的方法。其中，R1、R2、m和n如本文所定义。